Anixa Biosciences Secures Mexican Patent Extending Vaccine Protection into 2040
Anixa Biosciences secured Mexican Patent No. 432748 for its α-lactalbumin breast cancer vaccine, extending protection into 2040. Following Phase 1 results showing 74% immune response and full safety at maximum dose, Anixa is preparing for a Phase 2 trial to advance global commercialization.
1. Mexican Patent Granted
Anixa Biosciences received Patent No. 432748 from the Mexican Institute of Industrial Property, covering its α-lactalbumin breast cancer vaccine technology with protection through 2040 in a market noted for high triple-negative breast cancer incidence.
2. Phase 1 Clinical Data
Positive Phase 1 results showed the vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and elicited protocol-defined immune responses in 74% of participants across all doses.
3. Phase 2 Preparation
Based on Phase 1 safety and immunogenicity, Anixa is advancing its breast cancer vaccine into a Phase 2 trial, with trial design and site selection underway to assess efficacy and optimize dosing.
4. Global Commercial Strategy
By extending its patent estate into the 2040s across multiple jurisdictions, Anixa strengthens its position for global partnerships and eventual commercialization of its vaccine portfolio.